An interventional study of DPP4 and Insulin in Type 2 Diabetes Mellitus, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-08.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment
Prevalence of diabetes is increasing rapidly both in China and all over the world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and cerebrovascular diseases and even dangerous to human health."High glucose toxicity "cause pancreatic β cell non-physiologic and irreversible damage.It is an important cause of β cell dysfunction.High glucose toxicity further suppresses insulin secretion of β cell, further even β-cell function failure.It is urgent to explore more effective and safety treatments which can also protect islet cells function.How to release high glucose toxicity , reverse the toxic effects of hyperglycemia on islet β cells as early as possible, and to maximize recover and protect the pancreatic β cell function is the keypoints of this study.Our aim is to explore the non-inferiority of new antidiabetic drugs DPP4 inhibitors on releasing glucose toxicity and protecting islet β cell function compared with traditional treatments on newly diagnosed type 2 diabetes,compare efficacy and safety of different oral antidiabetic drugs and insulin on newly diagnosed type 2 diabetes patients with high glucose toxicity and compare differences of different oral antidiabetic drugs and insulin on protecting pancreatic β-cell function.
Patients were divided into 3 groups:
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 135 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 306 studies on the registry; 86 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
DPP4 inhibitor,1 pill qd
Drug: DPP4
insulin,glargine or detemir，0.2U/Kg,qd
Drug: Insulin
SU,Glimepiride，1-2mg qd
Drug: SU
sitagliptin phosphate 100mg qd
Also known as: sitagliptin phosphate
Insulin Glargine or detemir 0.2U/kg qd
Also known as: Glargine or detemir
Glimepiride 1-2mg qd
Also known as: Glimepiride
Fasting blood glucose,glycosylated hemoglobin(GHbA1c)
mmol/L,%
Time frame: From date of randomization until the date of first documented progression, assessed up to 3 months
weight loss
kilograms
Time frame: From date of randomization until the date of first documented progression, assessed up to 3 months
Lipid changes
mmol/L
Time frame: From date of randomization until the date of first documented progression, assessed up to 3 months
Incidence of hypoglycemia
times
Time frame: From date of randomization until the date of first documented progression, assessed up to 3 months
Plan to share: No
This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University